Ocumetics Reports Significant Vision and Quality-of-Life Improvements in Six-Month First-in-Human Lens Study

Ocumetics Technology Corp. announced highly encouraging six-month postoperative results from the first group of patients in its first-in-human clinical study of the Ocumetics Accommodating Intraocular Lens. Six months after surgery, patients who received the Ocumetics Lens have achieved clinical outcomes that meet and exceed the company's expectations. Group One patients entered the study with very poor vision, including one individual considered to be legally blind. At six months post-surgery, patients continue to demonstrate improved vision and stable visual acuity, alongside a strong safety profile.

Patients have also experienced real world transformation in their daily lives. Anecdotally, all patients reported life changing results from lens implantations. After six months, what stands out most is not just the clinical performance of the Ocumetics Lens, but the profound impact on patients' quality of life. Patients who entered this study with severely impaired vision are now reading, driving, and living independently again. The company is developing a technology that dramatically improves people's quality of life.

The measurable improvements in visual acuity and consistency seen at six months give the company tremendous confidence as it advances to the next phase of its clinical program. The results reinforce the expected performance of Ocumetics' inaugural accommodating intraocular lens. The company is not only validating its technology, it is demonstrating its real-world impact. The focus now is to build on this success, further optimize performance, and bring this life changing solution to more patients.

Ocumetics continues to leverage surgeon feedback and patient experience into ongoing product enhancements. Updated lens refinements are currently in manufacturing and testing, supporting the planned initiation of Group Two surgeries. Forward momentum continues, with lens design enhancements in manufacturing and testing phase. Ocumetics looks forward to initiating Group Two surgeries following completion of lens testing, as the company continues to advance its mission of transforming vision correction through innovation.

The company will host a webinar on April 22, 2026, at 4:00 PM ET to discuss these results. Interested parties can register at https://www.ocumetics.com/webinar. The original release can be viewed on https://www.newmediawire.com.